The pulmonary drug delivery industry specializes in innovative methods for administering medications directly to the lungs. This sector includes companies that produce inhalers, nebulizers, and drug formulations tailored for respiratory diseases like asthma and COPD. As healthcare shifts toward precision medicine, advancements in aerosol technology focus on maximizing drug deposition in the lungs. Emerging trends are pushing towards patient-centered inhalation devices that improve user experience and adherence. This industry is increasingly integrating digital health technologies, promising to enhance the effectiveness of pulmonary therapies and monitor treatment outcomes more effectively.

The list features a range of companies in pulmonary drug delivery, from startups to established firms. They vary in size, employing between 1 to 10,000 individuals, and are headquartered in regions like the United States, Europe, and Asia. Founded from as early as 1923 to recent startups like Transpire Bio in 2022, these companies focus on innovative inhalation technologies and drug-device combinations. Each firm showcases a unique specialization, whether it’s research and development or manufacturing inhalation devices.

Read on to discover the top pulmonary drug delivery companies.

Top 26 Pulmonary Drug Delivery Companies

1. Aerogen

• Website: aerogen.com
• Ownership type: Private Equity
• Headquarters: Barnacranny, Galway, Ireland
• Employee distribution: Ireland 55%, United States (USA) 20%, United Kingdom (UK) 3%, Other 23%
• Latest funding: Other (Grant), $10.5M, December 2019
• Founded year: 1997
• Headcount: 501-1000
• LinkedIn: aerogen

Aerogen, founded in 1997 and based in Galway, Ireland, is a private equity-backed medical device manufacturer focused on aerosol drug delivery technology for respiratory therapy. The company has developed a range of products, including the Aerogen Solo, Aerogen Ultra, and Aerogen Pro, which are designed to facilitate effective medication delivery for patients with respiratory conditions. Aerogen's technology is particularly noted for its vibrating mesh nebulizers, which optimize aerosol delivery across various therapeutic settings, from invasive mechanical ventilation to self-ventilating patients. The company has a significant presence in the market, having treated over 20 million patients globally and partnered with leading ventilator manufacturers. Aerogen's commitment to innovation is reflected in its extensive portfolio of international patents and clinical publications, underscoring its role in advancing pulmonary drug delivery solutions.

2. Chiesi Group

• Website: chiesi.com
• Ownership type: Private
• Headquarters: Parma, Emilia-Romagna, Italy
• Employee distribution: Italy 64%, Pakistan 3%, United Kingdom (UK) 3%, Other 30%
• Founded year: 1935
• Headcount: 5001-10000
• LinkedIn: chiesi-group

Chiesi Group, officially known as Chiesi Farmaceutici S.p.A., is an international biopharmaceutical company headquartered in Parma, Italy. Founded in 1935, the company has over 85 years of experience in the pharmaceutical sector. Chiesi focuses on the research, development, and commercialization of innovative therapeutic solutions, particularly in the areas of respiratory health, rare diseases, and specialty care. Their commitment to improving patient quality of life is evident in their extensive pipeline of products aimed at treating respiratory conditions. Chiesi operates in more than 100 countries and has established research and development centers across the globe, including locations in the United States, Canada, and China. The company has also adopted a B Corp certification, reflecting its dedication to social and environmental responsibility, which further enhances its reputation in the healthcare industry.

3. Vectura Group

• Website: vectura.com
• Ownership type: Corporate
• Headquarters: Chippenham, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 98%, Other 2%
• Latest funding: $197.5M, September 2024
• Founded year: 1997
• Headcount: 201-500
• LinkedIn: vectura

Vectura Group Limited, based in Chippenham, England, is a pharmaceutical development company founded in 1997. The company specializes in inhaled medicines and inhaler devices, providing a range of services that include formulation, pharmaceutical analysis, device platforms, process development, technical transfer, product manufacturing, and regulatory support. With a workforce of approximately 329 employees, Vectura has established itself as a key player in the inhalation drug delivery sector. Their extensive experience and scientific expertise enable them to assist clients in overcoming the challenges associated with developing inhaled products. Recently, Vectura received significant funding, which underscores their active role in the industry and their commitment to advancing inhalation therapies.

4. Respira Therapeutics, Inc.

• Website: respiratherapeutics.com
• Ownership type: Corporate
• Headquarters: Palo Alto, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, November 2015
• Founded year: 2010
• Headcount: 1-10
• LinkedIn: respira-therapeutics-inc-

Respira Therapeutics, Inc., based in Palo Alto, California, is a biotechnology firm dedicated to the development of innovative inhalation therapies for respiratory diseases. Founded in 2010, the company has a small team of around 17 employees, reflecting a focused approach to its mission. Respira's primary product candidate, RT234, targets pulmonary arterial hypertension (PAH) and is designed for as-needed use, offering a novel alternative to existing treatments that typically require continuous administration. The company employs advanced particle engineering and proprietary device technologies to enhance drug delivery to the lung periphery, aiming to improve patient outcomes. Currently, Respira is engaged in Phase 2 clinical trials to validate the efficacy and safety of RT234, demonstrating their active involvement in the pulmonary drug delivery sector. Their commitment to addressing significant unmet needs in respiratory care positions them as a relevant player in this industry.

5. H&T Presspart

• Website: presspart.com
• Ownership type: Family Owned
• Headquarters: Marsberg, North Rhine-Westphalia, Germany
• Employee distribution: Spain 32%, United Kingdom (UK) 28%, Germany 25%, Other 15%
• Founded year: 1970
• Headcount: 501-1000
• LinkedIn: presspart

H&T Presspart, founded in 1970 and based in Marsberg, Germany, is a family-owned pharmaceutical manufacturer that specializes in drug delivery devices and components. The company collaborates with global pharmaceutical firms to develop and produce innovative inhalation therapies, ensuring high-quality and reliable solutions for patients. H&T Presspart's extensive offerings include device development, regulatory support, and analytical services, which are tailored to meet the specific needs of their clients in the pharmaceutical industry. With a workforce of around 333 employees, the company operates across several countries, including Spain, the UK, Germany, and Switzerland. H&T Presspart is recognized for its high-volume precision manufacturing capabilities, including deep-drawn and injection-molded components, and has a significant presence in the metered-dose inhaler (MDI) market, with over 85% of the world's MDIs featuring their components. Their focus on sustainability and the development of low global warming potential (GWP) propellants further demonstrates their commitment to advancing the field of pulmonary drug delivery.

6. Transpire Bio

• Website: transpirebio.com
• Ownership type: Private
• Headquarters: Weston, Florida, United States (USA)
• Employee distribution: United States (USA) 97%, United Kingdom (UK) 3%
• Latest funding: Other (Grant), $12,000, July 2023
• Founded year: 2022
• Headcount: 51-200
• LinkedIn: transpire-bio

Transpire Bio Inc. is a biopharmaceutical company based in Weston, Florida, specializing in inhalation therapies. Founded in 2022, the company is dedicated to developing innovative inhaled drug delivery systems that aim to improve patient access to essential therapies for serious diseases. Their product line includes metered-dose inhalers, soft-mist inhalers, and dry powder inhalers, catering to both patients and healthcare providers. Transpire Bio's mission is to harness the power of inhaled drug delivery to enhance access to important therapies and create treatment options for diseases with limited therapeutic alternatives. The company has a strong focus on developing lower-cost generic alternatives for existing inhaled medicines, which addresses a significant gap in the market. Recently, they secured funding through a grant in July 2023, which supports their ongoing research and development initiatives. With a team that boasts over 150 years of combined experience in inhaled medicine development, Transpire Bio is positioned to make a meaningful impact in the pulmonary drug delivery industry.

7. Ferrer

• Website: ferrer.com
• Ownership type: Private Equity
• Headquarters: Barcelona, Catalonia, Spain
• Employee distribution: Spain 76%, Mexico 8%, Chile 3%, Other 13%
• Latest funding: December 2019
• Founded year: 1959
• Headcount: 1001-5000
• LinkedIn: grupo-ferrer-internacional

Ferrer, founded in 1959 and based in Barcelona, Spain, is a private equity-owned pharmaceutical company dedicated to improving patient experiences through innovative treatments for serious illnesses. With a workforce of approximately 2,099 employees, Ferrer operates primarily in Spain, Mexico, and Chile, and has a global presence in 128 countries. The company emphasizes research and development, particularly in the fields of pulmonary vascular and interstitial lung diseases. Ferrer is committed to ethical practices and social justice, aiming to enhance the healthcare experience for patients and professionals alike. Their recent activities include advancing research in Progressive Supranuclear Palsy and obtaining distribution rights for a treatment targeting Idiopathic Pulmonary Fibrosis, highlighting their active role in addressing pulmonary health issues. Ferrer also engages in expanded access programs, allowing patients to access investigational therapies, further demonstrating their commitment to patient care and innovation.

8. Aquilon Pharma

• Website: aquilonpharma.com
• Ownership type: Private
• Headquarters: Pepinster, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: aquilon-pharmaceuticals

Aquilon Pharma, founded in 2013 and based in Pepinster, Wallonia, Belgium, is a private pharmaceutical and biotechnology company. It emerged as a spin-off from the University of Liège, reflecting a strong academic foundation in its operations. The company is dedicated to developing advanced inhaled drug formulations, particularly targeting respiratory conditions like asthma and COPD. Aquilon Pharma's product portfolio includes formulations for nebulizers, soft mist inhalers, dry powder inhalers, and nasal products, catering to both healthcare providers and patients. Their proprietary excipient technology, HP-Betadex, enhances the pharmacology and lung deposition of existing drugs, making them more effective. The company is actively involved in clinical trials and research projects, demonstrating its commitment to innovation in the pulmonary drug delivery space.

9. CF PharmTech, Inc.

• Website: cfpharmtech.com
• Ownership type: Private Equity
• Headquarters: Wuxi, Jiangsu, China
• Employee distribution: China 100%
• Latest funding: Series E-K, $50.9M, July 2020
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: cf-pharmtech-inc-

CF PharmTech, Inc., founded in 2007 and based in Wuxi, Jiangsu, China, is a pharmaceutical company that specializes in the development and production of inhalation medications for respiratory diseases. The company focuses on conditions such as asthma and chronic obstructive pulmonary disease (COPD), providing healthcare providers and patients with effective treatment solutions. CF PharmTech operates with a strong emphasis on research and development, boasting a product pipeline that includes inhalation aerosols, powders, and nasal sprays. With over 30 patents and a dedicated team of around 100 researchers, the company is committed to advancing pulmonary drug delivery technologies. In July 2020, CF PharmTech completed a Series E-K funding round, raising over $50 million to support its growth and innovation efforts in the respiratory medication market.

10. VERO Biotech

• Website: vero-biotech.com
• Ownership type: Venture Capital
• Headquarters: Atlanta, Georgia, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $30.0M, January 2023
• Founded year: 2006
• Headcount: 201-500
• LinkedIn: vero-biotech

VERO Biotech, based in Atlanta, Georgia, is a medical device manufacturer founded in 2006. The company focuses on developing the GENOSYL® Delivery System, which provides inhaled nitric oxide therapy for patients suffering from pulmonary hypertension. This innovative system is designed to enhance patient care by delivering precise and reliable doses of nitric oxide, a critical treatment for various cardiopulmonary conditions. VERO Biotech serves hospitals and healthcare providers, emphasizing the importance of effective respiratory therapies. The company has recently raised $30 million in funding to accelerate the commercialization of its products, reflecting strong investor interest in their technology. Their commitment to improving patient outcomes in critical respiratory conditions positions them as a significant player in the pulmonary drug delivery industry.

11. Pari

• Website: pari.com
• Ownership type: Private
• Headquarters: Starnberg, Bavaria, Germany
• Employee distribution: Germany 86%, France 3%, United States (USA) 2%, Other 8%
• Founded year: 1906
• Headcount: 501-1000
• LinkedIn: pari-gmbh

Pari, based in Starnberg, Bavaria, Germany, is a private medical device manufacturer that has been operational since 1906. The company is dedicated to aerosol therapy and the development of inhalation devices, primarily targeting respiratory diseases like asthma, COPD, and cystic fibrosis. Their product lineup includes a variety of nebulizers, inhalation solutions, and accessories designed to enhance the delivery of medication to the lungs. Pari's commitment to innovation is evident in their eFlow technology, which optimizes the delivery of medications through vibrating membrane nebulizers. The company serves a broad customer base, including healthcare professionals and patients, ensuring effective inhalation therapy for symptom relief. With a workforce of around 395 employees, Pari maintains a strong presence in the European market, particularly in Germany, while also reaching customers in the United States and other countries.

12. Bespak

• Website: bespak.com
• Ownership type: Private
• Headquarters: Holmes Chapel, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 95%, United States (USA) 5%
• Latest funding: Other (Grant), $795,000, March 2012
• Founded year: 1959
• Headcount: 1001-5000
• LinkedIn: bespak

Bespak, founded in 1959 and based in Holmes Chapel, England, is a private medical device manufacturer that specializes in inhaled and nasal drug delivery systems. With a workforce of around 547 employees, the company has established itself as a key player in the pharmaceutical industry. Bespak designs, develops, and manufactures a variety of products, including pressurized metered dose inhalers (pMDIs), soft mist inhalers, and nasal delivery devices. Their primary customers are pharmaceutical companies seeking effective drug delivery solutions. Bespak operates with a strong emphasis on sustainability, actively working towards the development of climate-friendly propellants and innovative drug-device combinations. The company has also expanded its capabilities through collaborations and joint ventures, such as their partnership with Medspray to create Resyca, which focuses on soft mist inhalers. This strategic approach allows Bespak to support the entire lifecycle of inhaled and nasal drug delivery products, from early development to commercial manufacturing.

13. SRS Life Sciences Pte Ltd

• Website: srslife.com
• Ownership type: Private
• Headquarters: Singapore
• Founded year: 2001
• Headcount: 51-200
• LinkedIn: srs-life-sciences-pte-ltd.

SRS Life Sciences Pte Ltd is a private healthcare and pharmaceutical company based in Singapore, founded in 2001. The company is dedicated to addressing significant health challenges in emerging nations through innovative drug delivery systems, medical diagnostics, and therapies. Their portfolio includes solutions for diseases such as pneumonia and tuberculosis, which are critical health issues in many developing regions. SRS Life Sciences actively collaborates with healthcare providers and organizations to deliver effective solutions aimed at improving health outcomes. Their research and development efforts focus on drug repurposing and addressing antimicrobial resistance, particularly in drug-resistant tuberculosis. The company has also made strides in creating AI-enabled diagnostic tools and formulations that cater to the needs of vulnerable populations, such as children suffering from pneumonia. With a workforce of 51-200 employees, SRS Life Sciences is positioned to make a meaningful impact in the healthcare sector, particularly in the areas of respiratory health and infectious diseases.

14. invoX

• Website: invoxpharma.com
• Ownership type: Private
• Headquarters: Diepenbeek, Flanders, Belgium
• Employee distribution: United Kingdom (UK) 72%, Belgium 20%, United States (USA) 6%, Other 2%
• Founded year: 2021
• Headcount: 51-200
• LinkedIn: invox-pharma

invoX Pharma, founded in 2021 and based in Diepenbeek, Belgium, is a private biopharmaceutical company dedicated to creating innovative medicines for oncology and respiratory diseases. The company leverages next-generation technology platforms to develop therapies that meet significant medical needs. A notable aspect of their operations is the Respiratory Innovation Centre, which focuses on drug-device combination products. Their flagship product, the Softhaler®, is a next-generation soft-mist inhaler that aims to improve the delivery of medications to the lungs. This device is designed to be more effective and environmentally friendly compared to traditional inhalers. invoX's pipeline includes both clinical and pre-clinical candidates targeting respiratory conditions, showcasing their commitment to advancing treatment options for patients. Their strategic partnerships further enhance their capabilities in scientific innovation and product development.

15. Nemera

• Website: nemera.net
• Ownership type: Private Equity
• Headquarters: Fontaines-Sur-Saône, Auvergne-Rhône-Alpes, France
• Employee distribution: France 61%, United States (USA) 19%, Brazil 10%, Other 11%
• Latest funding: October 2018
• Founded year: 2015
• Headcount: 1001-5000
• LinkedIn: nemera

Nemera, founded in 2015 and based in Fontaines-Sur-Saône, France, is a medical device manufacturer that specializes in drug delivery device solutions and combination product services. The company collaborates with pharmaceutical, biotechnology, and generic industries to improve treatment efficacy and ensure safe medication delivery. Their offerings include device development, clinical manufacturing, and innovation support. Notably, Nemera has a strong focus on inhalation products, which are critical for pulmonary drug delivery. With a workforce of approximately 1,390 employees, they operate globally, with significant presence in France, the United States, Brazil, Germany, and Poland. Their commitment to patient-centric solutions and quality manufacturing makes them a notable entity in the drug delivery device market.

16. Armstrong Pharmaceuticals Inc

• Website: armstrong-pharma.com
• Ownership type: Private
• Headquarters: Canton, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1955
• Headcount: 51-200
• LinkedIn: armstrong-pharmaceuticals-inc

Armstrong Pharmaceuticals Inc, based in Canton, Massachusetts, is a private biopharmaceutical company that focuses on the development, manufacturing, and marketing of inhalation products. Founded in 1955, the company has established itself as a key player in the pulmonary drug delivery market. Armstrong operates state-of-the-art facilities equipped for high-speed automated filling and packaging of inhalation products. Their product line includes Metered Dose Inhalers (MDIs) and nasal spray formulations. A significant milestone for the company was the FDA approval of Primatene MIST®, the first and only over-the-counter asthma inhaler, which underscores their expertise in this area. Armstrong is committed to maintaining high standards of quality and regulatory compliance, ensuring that their products meet the needs of healthcare providers and patients alike.

17. Inhalon Biopharma

• Website: inhalon.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $2.0M, November 2022
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: inhalon-biopharma

Inhalon Biopharma, founded in 2018 and based in Durham, North Carolina, is a biotechnology company dedicated to developing inhaled antibody treatments for acute respiratory infections. The company is actively working on solutions for conditions such as respiratory syncytial virus (RSV), influenza, and SARS-CoV-2. Inhalon’s innovative platform utilizes muco-trapping antibodies, which are designed to effectively target and eliminate pathogens in the lungs. This approach not only aims to improve patient outcomes but also facilitates at-home treatment options, making it more convenient for patients. Inhalon has garnered attention and support through various funding initiatives, including a $7 million grant from the U.S. Army Medical Research and Development Command and additional funding from the National Institutes of Health. Their ongoing research and development efforts position them as a relevant player in the pulmonary drug delivery sector.

18. Avalyn Pharma

• Website: avalynpharma.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 91%, Spain 9%
• Latest funding: Series C, $175.0M, September 2023
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: avalyn-pharma-inc

Avalyn Pharma Inc, based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company founded in 2011. The company specializes in developing inhaled therapies aimed at treating rare respiratory diseases, particularly interstitial lung diseases like pulmonary fibrosis. Avalyn's primary focus is on reformulating existing medications, such as pirfenidone and nintedanib, into inhaled formulations to enhance treatment efficacy while minimizing side effects. Their lead candidate, AP01, is currently undergoing a Phase 2b clinical trial, demonstrating their active role in the industry. In September 2023, Avalyn secured $175 million in Series C funding, underscoring their potential for growth and innovation in the pulmonary drug delivery space. With a dedicated team and a clear therapeutic focus, Avalyn Pharma is positioned to make significant contributions to the management of rare respiratory diseases.

19. Monaghan Medical Corporation

• Website: monaghanmed.com
• Ownership type: Private
• Headquarters: Plattsburgh, New York, United States (USA)
• Employee distribution: United States (USA) 95%, Sierra Leone 3%, Georgia 3%
• Founded year: 1981
• Headcount: 51-200
• LinkedIn: monaghan-medical-corporation

Monaghan Medical Corporation, founded in 1981 and based in Plattsburgh, New York, is a private medical device manufacturer dedicated to respiratory care solutions. The company designs and produces a range of products that assist individuals suffering from asthma, COPD, and other respiratory conditions. Their offerings include well-known devices like the AEROCHAMBER and AEROECLIPSE nebulizers, which facilitate effective aerosol drug delivery. Monaghan Medical also emphasizes education and support for healthcare providers and patients, ensuring that their products are used effectively. The company operates a Global Aerosol Lab and Research Center, highlighting its commitment to innovation and research in respiratory care. With a workforce of around 109 employees, Monaghan Medical serves both consumers and healthcare organizations, aiming to improve the quality of life for users through its advanced medical devices.

20. Third Pole Therapeutics

• Website: pole3.com
• Ownership type: Venture Capital
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $32.0M, December 2022
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: third-pole-inc.

Third Pole Therapeutics, based in Waltham, Massachusetts, is a medical device company founded in 2014. The firm is dedicated to creating innovative therapies for cardiopulmonary diseases, with a particular emphasis on portable inhaled nitric oxide delivery systems. These systems are designed to enhance patient care in various healthcare environments, catering to both healthcare providers and patients. The company has made strides in its field, recently completing feasibility studies for its eNOfit™ portable inhaled nitric oxide device. Third Pole has attracted substantial investment, including a $32 million Series B funding round in December 2022, which supports the advancement of its technology and product offerings. Their commitment to improving treatment options for patients with severe respiratory conditions positions them as a notable player in the pulmonary drug delivery industry.

21. Rus BioPharm

• Website: rusbiopharm.ru
• Ownership type: Private
• Headquarters: Moscow, Moscow, Russia
• Employee distribution: Russia 100%
• Founded year: 2012
• Headcount: 201-500
• LinkedIn: rusbiopharm

Rus BioPharm, also known as ПСК Фарма, is a private biopharmaceutical company based in Moscow, Russia, founded in 2012. The company focuses on the development and manufacturing of high-tech medicinal products aimed at treating socially significant diseases, with a particular emphasis on asthma and chronic obstructive pulmonary disease (COPD). Rus BioPharm operates a full-cycle production facility located in the Dubna Special Economic Zone, where they synthesize active pharmaceutical ingredients and produce a comprehensive range of inhalation medications. The company has established itself as a significant player in the pulmonary drug delivery sector, claiming to hold the top position in the production of inhalation therapies in Russia. Their portfolio includes 23 active pharmaceutical ingredients that are recognized as the gold standard in asthma and COPD treatment. Rus BioPharm is committed to ensuring the safety and efficacy of its products through extensive clinical trials and ongoing pharmacovigilance, which involves monitoring the safety of their medications post-market. The company serves healthcare providers and patients, contributing to the improvement of respiratory health in the region.

22. Breath Therapeutics, a Zambon company

• Website: breath-therapeutics.com
• Ownership type: Corporate
• Headquarters: Munich, Bavaria, Germany
• Employee distribution: Germany 50%, United States (USA) 50%
• Latest funding: $156.0M, July 2019
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: breath-therapeutics

Breath Therapeutics, a Zambon company, is a pharmaceutical firm based in Munich, Germany, founded in 2016. The company specializes in innovative treatments for severe respiratory diseases, focusing on conditions such as Bronchiolitis Obliterans Syndrome (BOS) and Non-Cystic Fibrosis Bronchiectasis (NCFB). Breath Therapeutics is dedicated to developing effective medications that address significant unmet needs in these areas. Their approach includes clinical research and strategic partnerships aimed at bringing new therapies to market. Notably, they are advancing the development of Liposomal Cyclosporine A for inhalation, which is currently undergoing pivotal Phase 3 studies. This investigational therapy aims to deliver targeted treatment directly to the lungs, minimizing systemic exposure. The company has received substantial funding, amounting to over $156 million, which supports their ongoing research and development efforts.

23. Inke

• Website: inke.es
• Ownership type: Private Equity
• Headquarters: Barcelona, Catalonia, Spain
• Employee distribution: Spain 100%
• Latest funding: April 2023
• Founded year: 1980
• Headcount: 51-200
• LinkedIn: inke

Inke, founded in 1980 and based in Barcelona, Spain, is a private equity-owned pharmaceutical manufacturer. The company specializes in the development and production of active pharmaceutical ingredients (APIs) tailored for respiratory therapies. With over 20 years of experience, Inke has honed its expertise in micronization, a crucial process for creating fine particles suitable for inhalation. They offer contract manufacturing services and have a robust product portfolio that includes 12 respiratory APIs for inhalation. Inke has filed numerous Drug Master Files (DMFs) across various international markets, including Europe, the USA, Japan, and China, indicating their global reach and regulatory compliance. Their manufacturing facilities adhere to strict quality standards, ensuring that they meet the needs of pharmaceutical companies and healthcare organizations worldwide.

24. LABORATORIO CHIMICO DECA Dr. Capuani S.r.l.

• Website: labdeca.com
• Ownership type: Private
• Headquarters: Milan, Lombardy, Italy
• Employee distribution: Italy 100%
• Founded year: 1923
• Headcount: 51-200
• LinkedIn: laboratorio-chimico-deca-dr--capuani-s-r-l-

Laboratorio Chimico Deca Dr. Capuani S.r.l., founded in 1923 and based in Milan, Italy, is a pharmaceutical company dedicated to the research, development, and production of innovative therapies primarily aimed at treating respiratory diseases. With a workforce of approximately 146 employees, the company has built a reputation for delivering a range of pharmaceutical products that cater to healthcare professionals, hospitals, and pharmacies. Their offerings include various formulations designed to improve patient health outcomes, particularly in the field of respiratory health. The company has expanded its therapeutic targets over the years to include pediatrics, gastroenterology, and otorhinolaryngology, showcasing its adaptability and commitment to addressing multiple medical needs. Laboratorio Chimico Deca actively participates in medical congresses, emphasizing its engagement with the medical community and its focus on advancing treatment options for respiratory conditions.

25. Chiesi Brasil

• Website: chiesi.com.br
• Ownership type: Private
• Headquarters: Sao Paulo, Sao Paulo, Brazil
• Employee distribution: Brazil 100%
• Founded year: 1976
• Headcount: 201-500
• LinkedIn: chiesi-brasil

Chiesi Farmacêutica Ltda, established in 1976, is a Brazilian pharmaceutical company based in São Paulo. It specializes in the research, development, and commercialization of innovative medications, particularly in the therapeutic areas of respiratory health, neonatology, and rare diseases. The company is dedicated to improving patient outcomes and works closely with healthcare professionals to provide effective solutions. Chiesi Brasil operates manufacturing facilities in Brazil and is recognized for its commitment to sustainability and corporate responsibility. The company is also a certified B Corp, reflecting its dedication to social and environmental performance. With a workforce of approximately 403 employees, Chiesi Brasil plays a significant role in the pharmaceutical industry, particularly in the development of inhalation devices and treatments for respiratory conditions.

26. Mundipharma Germany GmbH & Co. KG

• Website: mundipharma.de
• Ownership type: Private
• Headquarters: Frankfurt, Hesse, Germany
• Founded year: 1967
• Headcount: 51-200
• LinkedIn: mundipharma-vertriebsgesellschaft-mbh-%26-co--kg

Mundipharma Germany GmbH & Co. KG, based in Frankfurt, Hesse, is a private research-based pharmaceutical company founded in 1967. The company specializes in developing innovative therapeutic solutions for serious health conditions, with a strong emphasis on oncology, pain management, and respiratory diseases. Mundipharma is dedicated to enhancing treatment outcomes through collaboration with healthcare professionals and institutions. Their product portfolio includes flutiform, a medication for asthma, showcasing their involvement in pulmonary drug delivery. The company operates globally, with a presence in multiple regions, and focuses on patient-centered care, ensuring that the needs of patients and healthcare providers are prioritized in their operations.

Pulmonary Drug Delivery Insights: Key Companies

Want to Find More Pulmonary Drug Delivery Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!